Figure 1.
PFS in TN CLL by higher-risk genomic feature. Shown are acalabrutinib-based regimens for (A) del(17p)/TP53m, (B) uIGHV, (C) CK overall, and (D) CK without del(17p)/TP53m. A, acalabrutinib; O, obinutuzumab.
PFS in TN CLL by higher-risk genomic feature. Shown are acalabrutinib-based regimens for (A) del(17p)/TP53m, (B) uIGHV, (C) CK overall, and (D) CK without del(17p)/TP53m. A, acalabrutinib; O, obinutuzumab.
